Efficacy and safety of TACE combined with lenvatinib and PD-1 inhibitors for unresectable recurrent HCC: A multicenter, retrospective study.

ABSTRACT:

Background

There is no consensus on the optimal regimen for unresectable recurrent hepatocellular carcinoma (HCC), so this retrospective study aimed to evaluate the efficacy and safety of transarterial chemoembolization (TACE) combined with lenvatinib and PD-1 inhibitors (T-L-P) versus TACE combined with lenvatinib (T-L) or TACE alone.

Method

Data were collected from 204 patients with unresectable recurrent HCC who received T-L-P, T-L, or TACE alone at three medical centers from January, 2019 to December, 2020 for analysis. The survival outcomes, tumor response, and adverse events were compared between three groups, and risk factors were further investigated.

Results

The median overall survival in the T-L-P, T-L, and TACE alone groups were not reached, 25.6, and 15.7 

SUBMITTER: Wang WJ 

PROVIDER: S-EPMC10242311 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature